DiaMedica Therapeutics Inc. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
DiaMedica Therapeutics Inc. (DMAC) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $303.00 thousand for the 3-month period ending 2021-09-30, per its 10-Q filed 2021-11-10.
Discontinued › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2021-11-10
- DiaMedica Therapeutics Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2021-09-30 was $303.00K, a 40.35% decline year-over-year.
- DiaMedica Therapeutics Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2021-06-30 was $446.00K, a 2.29% increase year-over-year.
- DiaMedica Therapeutics Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2021-03-31 was $511.00K, a 30.03% increase year-over-year.
- DiaMedica Therapeutics Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2020-09-30 was $508.00K.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month |
|---|---|---|---|
| 2021-09-30 | $303.00K 10-Q · filed 2021-11-10 | $749.00K derived: sum of 2 quarters · filed 2021-11-10 | $1.26M derived: sum of 3 quarters · filed 2021-11-10 |
| 2021-06-30 | $446.00K 10-Q · filed 2021-11-10 | $957.00K derived: sum of 2 quarters · filed 2021-11-10 | |
| 2021-03-31 | $511.00K 10-Q · filed 2021-11-10 | ||
| 2020-09-30 | $508.00K 10-Q · filed 2021-11-10 | $944.00K derived: sum of 2 quarters · filed 2021-11-10 | $1.34M derived: sum of 3 quarters · filed 2021-11-10 |
| 2020-06-30 | $436.00K 10-Q · filed 2021-11-10 | $829.00K derived: sum of 2 quarters · filed 2021-11-10 | |
| 2020-03-31 | $393.00K 10-Q · filed 2021-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |